Widespread cutaneous reaction to the Johnson & Johnson Ad26.COV2.S vaccine

To the Editor: We read with interest the report of the cutaneous eruption to Janssen Ad26.COV2.S vaccine by Lospinoso et al.1 We report another such reaction with slightly different clinical features, presenting with a largely cutaneous component.

The Janssen Ad26.COV2.S vaccine against COVID-19 represents the first single-dose option used in prevention of infection. It employs a viral vector using modified adenovirus DNA to produce the SARS-CoV-2 spike protein to illicit an immune response and has proven 66% effective in preventing COVID-19 infection.2-4 Only one severe hypersensitivity reaction and no anaphylactic reactions were reported during the safety and efficacy trials.3,4 On April 12, 2021, the Janssen Ad26.COV2.S vaccine distribution was temporarily suspended due to a rare side effect of cerebral venous sinus thrombosis combined with thrombocytopenia with antibodies to platelet factor 4; however, the vaccine distribution was resumed on April 23, 2021.5 We report a case of a diffuse erythematous dermatitis developing in a patient who received the Janssen Ad26.COV2.S vaccine.

An 80-year-old woman with a history of factor V Leiden, hypertension, hyperlipidemia, and chronic thrombocytopenia presented to the emergency department with febrile episodes and diffusely scattered, pruritic, erythematous-to-violaceous edematous plaques involving the entire cutaneous surface with shallow erosions of posterior oropharynx and mucosal lips (Fig 1).

Punch biopsy revealed spongiotic and interface dermatitis with superficial and deep lymphocytic infiltrate consistent with a drug eruption or viral exanthem. Laboratory evaluation at the time of presentation was remarkable only for thrombocytopenia and mild anemia. Extensive workup included chest X-ray, computed tomography of the abdomen and pelvis, throat culture, anti-streptolysin O, blood cultures, urinalysis, SARS-CoV-2 polymerase chain reaction, HIV1/2 antigen and antibodies, hepatitis C antibodies, viral respiratory panel, influenza A and B virus polymerase chain reaction, parvovirus IgG and Immunoglobulin M antibodies, antinuclear antibodies, anti-Smith antibodies, anti-double-stranded DNA antibodies, and C3 and C4, which were all normal. The patient underwent workup for her chronic thrombocytopenia with no evidence of overt malignancy. Bone marrow biopsy revealed normocellular marrow with trilineage hematopoiesis, and flow cytometry was negative for a clonal lymphoid or aberrant myeloid population. Increased numbers of macrophages with focal hemophagocytosis were noted on bone marrow biopsy. However, serum ferritin concentration was 273 ng/mL, and the patient did not meet the criteria for hemophagocytic syndrome. The patient denied any new medications (prescription or over the counter) or recent medication changes but reported receiving the Janssen Ad26.COV2.S vaccination 3 days prior to the development of her rash. She was treated with topical triamcinolone ointment, antihistamines (cetirizine 10 mg daily), and prednisone 20 mg daily with resolution of her eruption.

Although a direct causal relationship between the cutaneous eruption observed in our patient and the vaccination cannot be confirmed, extensive workup and thorough medication history revealed no other underlying cause. Our patient’s dermatitis proved non-life-threatening, and improvement was achieved with oral prednisone, antihistamines, and topical steroids.

Our case suggests a possible association of the Janssen Ad26.COV2.S vaccination with a
nonlife-threatening, diffuse cutaneous eruption. We are responding to expand the reported clinical presentations of reactions to the Janssen Ad26.COV2.S vaccine, while widespread reactions to the vaccine still appear to be exceedingly rare.

Josiah Sowell, BS,a Stephanie L. Bevans, MD,b and Carly A. Elston, MDb

From the University of Alabama at Birmingham, Alabamaa; and Department of Dermatology, University of Alabama at Birmingham, Alabama.b

Funding sources: None.

IRB approval status: Not applicable.

Correspondence to: Josiah Sowell, BS, The University of Alabama at Birmingham, 1720 University Blvd, Suite 500, Birmingham, AL 35294

E-mail: jwsowell@uab.edu

Conflicts of interest

None disclosed.

REFERENCES

1. Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021;13:134-137. https://doi.org/10.1016/j.jdcr.2021.05.010

2. Centers for Disease Control and Prevention. Johnson & Johnson’s Janssen COVID-19 vaccine overview and safety. Accessed April 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html

3. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson vaccine for COVID-19. JAMA. 2021;325(15):1575. https://doi.org/10.1001/jama.2021.2927

4. United States Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. FDA Briefing Document Janssen Ad26.-COV2.S vaccine for the prevention of COVID-19. Accessed April 4, 2021. https://www.fda.gov/media/146217/download

5. CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020—January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. https://doi.org/10.15585/mmwr.mm7004e1

https://doi.org/10.1016/j.jdcr.2021.08.037